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Background: We have previously shown that transforming growth factor-beta (TGF-beta) impairs glucocorticoid
(GC) function in pulmonary epithelial cell-lines. However, the signalling cascade leading to this impairment is
unknown. In the present study, we provide the first evidence that TGF-beta impairs GC action in differentiated
primary air-liquid interface (ALI) human bronchial epithelial cells (HBECs). Using the BEAS-2B bronchial epithelial cell
line, we also present a systematic examination of the known pathways activated by TGF-beta, in order to ascertain
the molecular mechanism through which TGF-beta impairs epithelial GC action.
Methods: GC transactivation was measured using a Glucocorticoid Response Element (GRE)–Secreted embryonic
alkaline phosphatase (SEAP) reporter and measuring GC-inducible gene expression by qRT-PCR. GC transrepression
was measured by examining GC regulation of pro-inflammatory mediators. TGF-beta signalling pathways were
investigated using siRNA and small molecule kinase inhibitors. GRα level, phosphorylation and sub-cellular
localisation were determined by western blotting, immunocytochemistry and localisation of GRα–Yellow Fluorescent
Protein (YFP). Data are presented as the mean ± SEM for n independent experiments in cell lines, or for experiments on
primary HBEC cells from n individual donors. All data were statistically analysed using GraphPad Prism 5.0 (Graphpad,
San Diego, CA). In most cases, two-way analyses of variance (ANOVA) with Bonferroni post-hoc tests were used to
analyse the data. In all cases, P <0.05 was considered to be statistically significant.
Results: TGF-beta impaired Glucocorticoid Response Element (GRE) activation and the GC induction of several
anti-inflammatory genes, but did not broadly impair the regulation of pro-inflammatory gene expression in A549
and BEAS-2B cell lines. TGF-beta-impairment of GC transactivation was also observed in differentiated primary
HBECs. The TGF-beta receptor (ALK5) inhibitor SB431541 fully prevented the GC transactivation impairment in the
BEAS-2B cell line. However, neither inhibitors of the known downstream non-canonical signalling pathways, nor
knocking down Smad4 by siRNA prevented the TGF-beta impairment of GC activity.
Conclusions: Our results indicate that TGF-beta profoundly impairs GC transactivation in bronchial epithelial cells
through activating ALK5, but not through known non-canonical pathways, nor through Smad4-dependent signalling,
suggesting that TGF-beta may impair GC action through a novel non-canonical signalling mechanism.
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Glucocorticoids are the most effective class of anti-
inflammatory drugs available. However, several chronic
inflammatory diseases appear to be inherently resistant to
glucocorticoid therapy [1]. Even in disease states where
glucocorticoids are usually effective, patient sensitivity to
glucocorticoid action varies dramatically. Indeed, different
tissues from the same patient may even differ in sensi-
tivity, suggesting that it is the chronic inflammatory
microenvironment that is responsible for localized re-
sistance to glucocorticoid action [2,3]. Several biochemical
alterations have been associated with glucocorticoid resist-
ance including increased levels of cytokines (TNFα, IFNγ,
IL-2, IL-4, IL-13, IL-17, IL-27, MIF), oxidative and nitra-
tive stress, and the presence of denatured collagen [1,4,5].
Despite the identification of these associations, the eluci-
dation of the activation of downstream signalling pathways
and the resultant impairment of the action of the gluco-
corticoid receptor, glucocorticoid resistance remains a
major obstacle in the treatment of chronic inflammatory
diseases.
Appreciation for the role of airway epithelial cells as a
target for glucocorticoid therapy is ever increasing. The
epithelium is the site of deposition for inhaled glucocor-
ticoids, and as such can be exposed to much higher con-
centrations of glucocorticoid than any other cell type in
the airway. A corollary of the importance of airway epi-
thelial cells as a target for glucocorticoid activity is that
it is also a key cell type in which glucocorticoid resist-
ance may develop. There have been limited numbers of
studies investigating the molecular mechanisms of resist-
ance in epithelial cells, as opposed to the extensive atten-
tion paid to inflammatory cell types [4]. It is known,
however, that inflammatory stimuli such as TNFα, and
mitogens such as foetal calf serum (FCS), can induce re-
sistance to glucocorticoid transactivation in epithelial cells
[6]. Similarly, IL-17A has been found to induce resistance
to glucocorticoid regulation of IL-8 production in epi-
thelial cells [7]. Very recently, rhinovirus infection has
also been shown to cause glucocorticoid resistance in
airway epithelium through the activation of NFκB and
JNK and impaired nuclear entry of GRα [8]. The epithe-
lium is therefore gaining increasing attention as a cell
type in which glucocorticoid resistance can develop.
We have previously shown that transforming growth
factor-beta (TGF-β) impairs GRE-dependent transa-
ctivation and glucocorticoid regulation of interleukin-6
and interleukin-8 production in the A549 lung adeno-
carcinoma-derived epithelial cell line, in association with
decreased nuclear translocation of GRα [9]. This resist-
ance was not restricted to the A549 cell line, as TGF-β
was also shown to impair glucocorticoid regulation of
thrombin and IL-1 stimulated GM-CSF release from
BEAS-2B bronchial epithelial cells. However, the precisemolecular mechanism(s) through which TGF-β impairs
glucocorticoid function is yet to be established in either
cell line, or in primary bronchial epithelial cells.
TGF-β is renowned for its pleiotropic actions on a
wide variety of signalling pathways. Depending on the
cellular context, TGF-β can activate Smad proteins
resulting in transcriptional regulation, and it can acti-
vate a wide variety of non-canonical pathways, such as
MAP kinase pathways, phosphoinositide 3-kinase (PI3K)
and Rho pathways. The NFκB pathway is also activated
through increased IKK activity [10]. In the present study,
we provide the first evidence that TGF-beta impairs GC
action in the ‘gold standard’ in vitro epithelial model:
differentiated primary air-liquid interface (ALI) human
bronchial epithelial cells (HBECs). Furthermore, using the
BEAS-2B bronchial epithelial cell line, we also present a
systematic examination of the known pathways activated
by TGF-beta, in order to ascertain the molecular mechan-
ism through which TGF-beta impairs epithelial GC action.
Materials and methods
Cell culture
A549 lung adenocarcinoma and BEAS-2B bronchial epi-
thelial cell lines were cultured as described [9]. Primary
HBECs were purchased from Lonza (Waverley, Australia)
and cultured using B-ALI™ BulletKit™ (Lonza) according
to manufacturer’s instructions.
Air-liquid interface differentiation of primary HBECs
Primary HBECs were differentiated on fibrillar collagen-
coated 24-well Corning® Transwell® inserts (Sigma #CLS
34700, MO, USA) by culture at air-liquid interface for
4 weeks. Cell differentiation was confirmed through visu-
alisation of beating cilia and measurement of trans-
epithelial electrical resistance (TEER) using an EVOM2
Voltohmmeter (WPI, Sarasota, FL). Cells were treated
with 40 pM TGF-β or control for 24 h, then stimulated
with 100 nM dexamethasone (Dex), 100 nM budesonide
(Bud) or vehicle control for 4 h after which total RNA was
extracted and GC-inducible gene expression was mea-
sured by qRT-PCR.
Transfection of epithelial cells
BEAS-2B cells were co-transfected using Lipofectamine®
2000 (Invitrogen, Carlsbad, CA) as previously described
[9]. Plasmid vectors: pGRE-SEAP (Clontech Laboratories
Inc., Mountain View, CA), pSM22-Luc [11], GRα-YFP
construct (a kind gift from Prof John Cidlowski [12]).
pmax-GFP (Amaxa, Lonza, Waverley, Aus) and pGL3-
Luc (Promega, Alexandria, NSW, Aus) were used as
internal transfection controls. Transfected cells were
treated with TGF-β (4–100 pM) for 24 h prior to the
addition of dexamethasone (Dex, 0.1-100 nM) or vehicle
for 2 h. GFP and YFP expression were imaged using
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microscope. Supernatants were collected for measurement
of secreted human placental alkaline phosphatase (SEAP)
using a chemiluminescence kit (Roche Applied Science,
NSW, Aus). Luciferase expression was determined from
lysates prepared by scraping cells in 25 mM tris-
phosphate buffer (pH 7.8) containing 10% glycerol, 1%
triton X-100, 1 mg/mL BSA, 2 mM EDTA, 2 mM DTT.
Cell lysate luciferase luminescence activity was deter-
mined by reagent buffer consisting of 20 mM Tris
(pH 7.8), 33.3 mM DTT, 8 mM MgCl2, 0.13 mM EDTA,
0.47 mM Beetle Luciferin (Promega #E1601). siRNA
targeting exon 7 of Smad4 (sense: 5′-GCCAUAGU-
GAAGGACUGUUtt-3′, Shanghai Genepharma, Shanghai,
China), was transfected using Lipofectamine RNAiMAX
(Invitrogen) as described previously [13].RNA extraction and RT-qPCR
Total RNA was purified from A549 and BEAS-2B cell
lines using TRIzol (Invitrogen, Doncaster, VIC, Australia),
and from differentiated HBECs using RNeasy miniprep kit
(Qiagen, Doncaster, VIC, Australia). RNA (100 ng) was
reverse-transcribed in a 5 μL reaction using the High
Capacity cDNA Reverse Transcription Kit (Applied Bio-
systems, Scoresby, VIC, Australia) then diluted with
145 μL DEPC-treated H2O. Real-time PCR was per-
formed using ABI Prism 7900HT sequence detection
system as previously described [9]. The generation of
specific PCR products was confirmed by dissociation
curve analysis. Primer sequences (Table 1) were ob-
tained either from literature, or designed using Primer
Express software (Applied Biosystems) with mRNA se-
quences from the National Centre for Biotechnology
Information (http://www.ncbi.nlm.nih.gov).Table 1 Primer Sequences for RT-PCR
Gene product Forward primer
18S CGC CGC TAG AGG TGA AAT
CDKN1C TCT GAT CTC CGA TTT CTT CG
ENaCα AGC ACA ACC GCA TGA AGA C
FKBP5 AGA TTG AGC TCC TTG ATT TC
GILZ TCC TGT CTG AGC CCT GAA GAG
GRβ TCA ACT GAC AAA ACT CTT GG
IκBα TAC CAA CTA CAA TGG CCA CAC
MKP-1 CCA CAA GGC AGA CAT CAG CTC
PAI-1 TCA GGC TGA CTT CAC GAG TCT T
SERPINA3 TCA AGA CAA GAT GGA GGA AG
SLPI GCA TCA AAT GCC TGG ATC CT
SMAD4 CCA GGA TCA GTA GGT GGA AT
Tektin-1 ATT ACA GCT CTT GAA AAG GCQuantification of IL-6 and PGE2 levels in supernatants
Supernatant IL-6 was assayed by Enzyme-linked Immuno-
sorbent Assay (ELISA) (Becton Dickinson, Heidelberg,
Germany) [9]. The level of PGE2 was measured by radio-
immunoassay (RIA) according to previous studies [14]
using commercial anti-PGE2 antiserum (Sigma #P5164).GR expression, phosphorylation and sub-cellular
localization
Glucocorticoid receptor expression and phosphorylation
state was investigated by western blot analysis as described
[13] using polyclonal antibodies directed against GRα,
phospho-GR(Ser203), phospho-GR(Ser211), phospho-GR
(Ser226) (Santa Cruz Biotechnology). The levels of pro-
tein and β-actin (β-actin mouse monoclonal: Abcam,
Cambridge, UK) were used to control for loading. GR
subcellular localization was determined by GRα-YFP
transfection (described above) and immunocytochem-
istry against GRα as described [9].Cell viability
Cell viability was assessed using the Trypan blue exclu-
sion method [13]. Cell viability was determined to be
>95% at the conclusion of all experimental treatment
periods in these studies.Statistical analyses
Data are presented as the mean ± SEM for n individual
experiments. All data were statistically analysed using
GraphPad Prism 5.0 (Graphpad, San Diego, CA). In
most cases, two-way analyses of variance (ANOVA) with
Bonferroni post hoc tests were used to analyse the data. A P
value of <0.05 was considered to be statistically significant.Reverse primer
TCT TGG CAA ATG CTT TCG CTC
CTC TTT GGG CTC TAA ATT GG
TGA GGT TGA TGT TGA GGC TG
TGA ATA TCC CTC TCC TTT CC
AGC CAC TTA CAC CGC AGA AC
AGT GCA CAT AAT CTT CTT TTT CTC A
G TAG CCA TGG ATA GAG GCT AAG TGT AGA
TCT ATG AAG TCA ATG GCC TCG TT
T CTG CGC GAC GTG GAG AG
TCA CCT ATC TCT CTG AAC TC
GCA TCA AAC ATT GGC CAT AAG TC
GTC TAA AGG TTG TGG GTC TG
GGG CTA AAG TTT CCT TCA ATC
Keenan et al. Respiratory Research 2014, 15:55 Page 4 of 14
http://respiratory-research.com/content/15/1/55Results
TGF-β impairs glucocorticoid transactivation in BEAS-2B
cells
In BEAS-2B cells transfected with a plasmid bearing
a GRE-controlled SEAP expression vector, incubation
with TGF-β potently and extensively inhibited Dex-
induced GRE activity with 4 pM sufficient to inhibit the
maximum response by 50%, and complete inhibition
observed at 40 pM TGF-β (Figure 1A). The GRE within
the GRE-SEAP construct may respond differently to
the GREs within the sequences of endogenous GRE-
regulated genes in their orthotopic genomic context.
Thus, measurement of the mRNA expression of a variety
of GRE-inducible genes was used to assess the effect of
TGF-β on dexamethasone-stimulated transactivation in
the BEAS-2B cell line. Of the panel of genes assessed,
the expression of most were markedly impaired. For
example, the genes encoding epithelial sodium channel-α
subunit (ENaCα), NFκB inhibitor-α (IκBα), glucocorticoid-
inducible leucine zipper (GILZ) (Figure 1B), annexin 1
(ANXA1) and secretory leukocyte protease inhibitor (SLPI)
(data not shown) were all impaired. The expression of some
genes, however, was unchanged or enhanced at the time-Figure 1 Effect of TGF-β on glucocorticoid transactivation. BEAS-2B cel
dexamethasone (1-100 nM). (A) GRE activity was measured in BEAS-2B cells tr
TGF-β (4-100 pM), then stimulated with dexamethasone for a further 24 hours
the level induced in response to 30nM dexamethasone. (B) Glucocorticoid-ind
incubated with TGF-β (40 pM) for 24 h before stimulation by dexamethas
qRT-PCR. Gene expression is expressed as fold change from control. Data
*P < 0.05, **P < 0.01, *P < 0.001 c.f. Control (A), 30 nM Dex (B).point measured. For example, the expression of the
gene encoding MAP kinase phosphatase 1 (MKP-1) was
enhanced by TGF-β conditioning prior to dex exposure
(Figure 1B).
TGF-β does not cause widespread impairment of
glucocorticoid regulation of cytokine production in
epithelial cell lines
In order to measure the effect of TGF-β on GC transre-
pression, we examined the glucocorticoid regulation of
pro-inflammatory gene expression. In the BEAS-2B cell
line, we examined the expression of genes widely accepted
to be regulated by transrepression. We found, as expected,
that the pro-inflammatory cytokine TNFα significantly
induced the expression of the genes encoding IL-6 and IL-
8 in a dexamethasone-sensitive manner (Figure 2A). TGF-
β alone induced the expression of IL-6 mRNA and further
enhanced the induction by TNFα. Nevertheless, this in-
duction of IL-6 mRNA was suppressed by dexametha-
sone, and the presence of TGF-β did not significantly
reduce the level of inhibition by dex (Figure 2A,B). A
similar pattern of results was observed for the regula-
tion of COX-2 mRNA (Figure 2A). Although TGF-βls were incubated with TGF-β (4-100pM) for 24 h before stimulation by
ansiently transfected with a GRE-SEAP reporter construct, incubated with
. The level of SEAP in the supernatants was expressed as a percentage
ucible gene expression in non-transfected cells. BEAS-2B cells were
one (30 nM) for 4 h after which RNA was extracted and analysed by
are presented as mean and SEM for n = 4 independent experiments.
Figure 2 Effect of TGF-β on glucocorticoid transrepression. (A) BEAS-2B cells were incubated with TGF-β (40pM) for 24 h, then incubated
with dexamethasone (30 nM) for 30 min prior to stimulation with TNFα (10 ng/mL) for 4 h. RNA was then extracted and expression was analysed
by qRT-PCR and expressed as fold change from control. (B) Data from (A) and (C) expressed as percentage inhibition by dexamethasone in the
presence and absence of TGF-β. (C) A549 cells were incubated with TGF-β (40 pM) for 24 h, then incubated with dexamethasone (10 nM) for
30 min prior to stimulation with IL-1α (1 ng/mL) for 4 h (Gene expression) or 24 h (PGE2 determination). Gene expression was determined as in
(A), PGE2 levels were determined by radioimmunoassay. Data are presented as mean and SEM for n = 3-4 independent experiments. *P < 0.05,
**P < 0.01, ***P < 0.001.
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dexamethasone was similarly effective in inhibiting IL-8
expression in the presence and absence of TGF-β
(Figure 2B).
We had previously shown that dexamethasone regula-
tion of IL-8 production is impaired by TGF-β in the
A549 cell line [9]. However, as this was not observed in
the BEAS-2B cell line, we decided to further examine the
effect of TGF-β on glucocorticoid repression of cytokineexpression in the A549 cell line to establish whether the
TGF-β effect is specific to IL-8 regulation, or extends to
the breadth of transrepressional impacts in this cell line.
IL-1α significantly induced IL-6 and IL-8 mRNA in a
dexamethasone-sensitive manner in the A549 cell line
(Figure 2C). TGF-β enhanced the IL-1α stimulation of
both IL-6 and IL-8 mRNA (Figure 2C). Dexamethasone
significantly suppressed the enhanced IL-6 and IL-8
mRNA in the presence of TGF-β (Figure 2C). However,
Keenan et al. Respiratory Research 2014, 15:55 Page 6 of 14
http://respiratory-research.com/content/15/1/55the extent of the suppression of IL-8 mRNA was reduced
in the presence of TGF-β (Figure 2B). Interestingly, dexa-
methasone was similarly effective at inhibiting IL-6 mRNA
(and IL-6 protein release, data not shown) in the presence
and absence of TGF-β in the A549 cell line, similar to the
BEAS-2B cell line (Figure 2B). Dexamethasone regulation
of PGE2 production and COX-2 mRNA expression was
also similar in the presence and absence of TGF-β in the
A549 cell line, despite an inhibition of PGE2 production
and a stimulation of COX-2 expression by TGF-β alone
(Figure 2C).
TGF-β impairs glucocorticoid transactivation in
differentiated primary HBECs
Primary HBECs met the criteria for ALI differentiation,
including TEER values greater than 700 Ω/cm2 (data
not shown) and increased Tektin-1 mRNA expression
(Figure 3), a marker of ciliated cell differentiation.
TGF-β impaired Dex-induced expression of several
anti-inflammatory genes, including the genes encoding
GILZ and ENaCα in ALI differentiated cells (Figure 3).
Consistent with observations in epithelial cell lines, the
expression of MKP-1 was not impaired followingFigure 3 Effect of TGF-β on glucocorticoid transactivation in air-liquid
cells. Primary human bronchial epithelial cells (HBECs) were differentiated
for 24 h, then stimulated with 100 nM dexamethasone (Dex) or vehicle con
expression was measured by qRT-PCR. Gene expression is expressed as fold
differentiated cells from n = 4 individual donors. ns P > 0.05, *P < 0.05, **P <incubation with TGF-β (Figure 3). TGF-β also impaired
budesonide-induced gene expression in a similar pat-
tern (data not shown).
TGF-β-induced impairment of glucocorticoid action is due
to activation of activin-like kinase 5, but not due to
activation of known non-canonical signalling pathways
Impairment of glucocorticoid action in the A549 cell
line was found to be associated with activation of the
activin-like kinase 5 (ALK5/TGFβRI kinase) receptor,
but the downstream signalling pathways activated have yet
to be elucidated. We therefore investigated the involve-
ment of the ALK5 receptor in the BEAS-2B cell line using
the selective ALK5 inhibitor SB431542 (1 μM), and other
commonly used and well-characterized small molecule in-
hibitors (1–10 μM based on our previous use [9,15] or the
use of others [16-19]) of the known non-canonical sig-
nalling pathways of TGF-β to examine which one or
more of the downstream pathways may be involved. In-
hibition of ALK5 using SB431542 completely prevented
TGF-β-induced impairment of GRE activation in the
BEAS-2B cell line. However, inhibitors of the down-
stream non-canonical signalling pathways had no effect on-interface (ALI) differentiated primary human bronchial epithelial
at air-liquid interface for 28 days, treated with 40 pM TGF-β or control
trol for 4 h after which total RNA was extracted and GC-inducible gene
change from control. Data are presented as mean and SEM from
0.01, *P < 0.001.
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conceivable that activation of more than one down-
stream pathway is responsible for impairment of glu-
cocorticoid action, multiple inhibitors were used to
simultaneously block multiple pathways, but no effect
was observed on TGF-β-induced GRE impairment (data
not shown).TGF-β-induced impairment of glucocorticoid action is not
dependent on Smad4
Smad4-targeted siRNA was used to examine canonical
TGF-β signalling, since this protein forms a unique, com-
mon point within canonical TGF-β signalling pathways.
Smad4-targeted siRNA resulted in a knockdown of more
than 60% which persisted throughout the experimental
period (Figure 5A). A concomitant impairment of Smad-
dependent gene expression was confirmed by measurement
of PAI-1 expression, along with a complete impairment of
TGF-β-induced SM22 promoter activity (Figure 5B).
However, neither GC-induced gene expression, nor its
impairment by TGF-β, was affected by Smad4 knock-
down (Figure 5C).Figure 4 Inhibition of known TGF-β non-canonical signalling
pathways does not prevent the impairment of GRE activity.
BEAS-2B cells transiently transfected with GRE-SEAP reporter construct
were pre-incubated for 30 min with inhibitors (1 μM SB431542: TGF-β
type 1 activin receptor-like kinase (ALK) receptors, 10 μM LY294002:
non-selective PI3-kinase inhibitor, 1 μM U0126: MEK1/2 inhibitor, 1 μM
SB202190: p38MAPK inhibitor, 10 μM 5Z-7-oxozeaenol: TAK1 inhibitor,
1 μM SP600125: JNK inhibitor, 10 μM IKK2 inhibitor VIII: selective IKK2
inhibitor, 10 μM TDZD-8: selective GSK-3 inhibitor) prior to the addition
of 40pM TGF-β for 24 h and stimulation with 30nM dexamethasone for
a further 24 h. Supernatants were then collected for determination of
SEAP level and results were then expressed as a percentage of the
level induced in response to 30nM dexamethasone. Data are
presented as mean and SEM for n = 3-4 independent experiments.
*P < 0.05, **P < 0.01, ***P < 0.001 significantly different from
control expression.TGF-β-induced impairment is not associated with either
impaired GRα expression, nuclear localization or altered
GRα phosphorylation status in the BEAS-2B cell line
In the A549 cell line, TGF-β-induced glucocorticoid im-
pairment was partially attributed to impaired nuclear
localization of GRα. We therefore investigated the po-
tential relevance of this mechanism in BEAS-2B cells
using live cell fluorescence microscopy of cells transi-
ently transfected with a GRα-YFP construct. Localization
of GRα-YFP fluorescence indicated that TGF-β did not
affect the rate or extent of GRα nuclear localization fol-
lowing dexamethasone treatment (Figure 6A, Additional
file 1). This observation was confirmed by immunofluor-
escence staining of non-transfected cells where equiva-
lent GRα immunoreactivity was observed in both
nuclear and cytoplasmic compartments of TGF-β treated
and control cells (Figure 6B).
Determination of GRα protein expression showed
a significant reduction by 30 nM dexamethasone treat-
ment, according with expectations based on previous
studies in A549, BEAS-2B and HeLa epithelial cell lines
[20,21]. However, treatment with TGF-β did not affect
either the level, or the down-regulation in the presence
of dexamethasone (Figure 6C). Similarly, dexametha-
sone treatment altered the phosphorylation state of
GRα according to expectations [22] with an increase in
phosphorylation at serine 203 and serine 211 observed,
and a decrease in phosphorylation at serine 226. Treat-
ment with TGF-β had no effect on either basal phosphor-
ylation state or the dexamethasone-induced changes in
phosphorylation. Up-regulation of the non-ligand binding
splice variant of the glucocorticoid receptor, GRβ, has
been proposed to impair glucocorticoid activity through
inhibiting the actions of GRα [23-25] or through the
recruitment of histone deacetylases (HDACs) [26].
qRT-PCR using validated primers to amplify GRβ did
not produce a detectable product after 40 cycles of PCR
for either control, dexamethasone-treated, or TGF-β
treated cells.
TGF-β-induced impairment of glucocorticoid action is not
a result of epigenetic repression of gene transcription
Epigenetic modifications such as DNA methylation through
DNA methyltransferase (DNMT) and histone deacetylation
through histone deacetylase (HDAC) are known to cause
repression of gene transcription. We therefore exam-
ined whether 5-aza-2′deoxycytidine, a DNMT inhibitor,
or Trichostatin A, an HDAC inhibitor, can prevent the
impairment of glucocorticoid transactivation by TGF-β.
However, inhibitors of DNMT or HDAC had no effect on
the dexamethasone-induced expression of the genes en-
coding cyclin-dependent kinase inhibitor 1C (CDKN1C)
and ENaCα (SCNN1A), nor the impairment of gene tran-
scription by TGF-β (Figure 7).
Figure 5 Smad4 does not mediate TGF-β induction of glucocorticoid insensitivity. Smad4 targeted siRNA reduces Smad4 expression (A),
Smad-dependent gene expression and the activity of the Smad-dependent promoter of SM22 (B), but does not alter the level of impairment of
GC-inducible gene activity by TGF-β (C). BEAS-2B cells were transfected with scrambled control or Smad4-targeted siRNA, then incubated with
TGF-β (40 pM) for 24 h, followed by stimulation with Dex (30 nM) for 4 h. Data are presented as mean and SEM for n = 4 independent experiments.
*P < 0.05, **P < 0.01, ***P < 0.001.
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Figure 6 TGF-β does not influence glucocorticoid-induced GRα nuclear localization. (A) BEAS-2B cells transiently transfected with a
GRα-YFP reporter construct were treated with TGF-β (40 pM) for 24 h then imaged before and after treatment with 30 nM dexamethasone
(Dex), using time-lapse live-cell fluorescence microscopy (Leica DMI 6000B). Images were obtained every 30 sec for 30 min prior to Dex
treatment, and for 2 h post-treatment. (B) Immunofluorescence of GRα in non-transfected BEAS-2B cells. Cells were incubated using an
identical protocol to that in (A) except that at the end of the 2 h dexamethasone incubation, cells were fixed with 10% NBF then GRα
immunolocalisation was probed with a FITC-labelled secondary antibody, and nuclei were co-stained with DAPI. Images presented are
representative of four independent experiments. (C,D) Protein expression and phosphorylation state of GRα. Cell lysates from BEAS-2B cells
were collected after 24 h treatment TGF-β (40pM), then 1 h treatment with 30nM dexamethasone. SDS-PAGE and immunoblotting using
phospho-specific antibodies was performed, then the membrane was stripped and re-probed for total GRα expression for normalization.
GRα expression was then normalized to β-actin expression. Data are presented as mean and SEM of 4 experiments. *P < 0.05, significantly
different from control expression.
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Figure 7 Effect of inhibitors of DNMTs and HDACs on TGF-β
impairment of glucocorticoid-inducible gene expression. Effect
of DNA methyltransferase (DNMT) inhibitor 5-aza-2′-deoxycytidine
and HDAC inhibitor trichostatin A on TGF-β impairment of
glucocorticoid-inducible gene expression. BEAS-2B cells were incubated
with inhibitors for 30 min prior to treatment with TGF-β (40 pM) for 24 h
before stimulation by dexamethasone (30 nM) for 4 h after which RNA
was extracted and analysed by qRT-PCR. Gene expression is expressed
as fold change from control. Data are presented as mean and SEM for
n= 3-4 independent experiments *P< 0.001.
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In this study, we have sought to ascertain the precise
molecular mechanisms through which TGF-β impairs
glucocorticoid action in epithelial cells. In order to suc-
cessfully do this, it is necessary to first have a thorough
understanding of the scope of impairment of gluco-
corticoid function. This study demonstrated that whilst
TGF-β has a profound inhibitory effect on glucocorticoid
transactivation, transrepressional mechanisms appear to
remain intact. Since it is commonly accepted that gluco-
corticoids produce the majority of their anti-inflammatory
effects through the repression of pro-inflammatory path-
ways [27], one might question whether the impairment of
GC transactivation by TGF-β is a therapeutically relevant
problem. One might even contend that TGF-β impair-
ment of GC transactivation might be beneficial to the
treatment of patients, since the multitude of side-effects
from GC treatment [28] have been commonly thought to
occur through transactivation mechanisms [29]. These
dogmas, however, have never been universally accepted,and it is increasingly accepted that transactivational induc-
tion of anti-inflammatory genes such as Annexin 1, GILZ
and MKP-1 are key to the anti-inflammatory actions of
glucocorticoids [30,31]. Moreover, it has recently been
reported that side effects of glucocorticoids are closely
associated with transrepression of nGRE-containing genes,
rather than transactivation of pGRE-containing genes [32].
We contend, therefore, that transactivation is an import-
ant anti-inflammatory mechanism of glucocorticoids, and
the very potent effect of TGF-β to completely suppress
GRE activity, and markedly impair GC-inducible gene
expression, is likely to contribute to glucocorticoid resist-
ance observed in clinical settings.
The complexity of glucocorticoid molecular mecha-
nisms is continuing to be unravelled. The simple story of
transactivation of pGRE-containing genes, tethered trans-
repression of pro-inflammatory transcription factors, in
particular NFκB and AP-1, and a couple of examples of
nGRE-containing repressed genes, has long been outdated.
In this study, we examined transactivational mechanisms
through an examination of both GRE-dependent pro-
moter activity and GC-inducible gene expression changes.
Whilst 40pM TGF-β caused complete inhibition of GRE
activity, not all GRE-containing genes are inhibited at this
concentration, and those that are exhibit varying degrees
of inhibition, suggestive of discordance between GRE sup-
pression and the impairment of gene expression. This,
however, is neither surprising nor unexpected. Synthetic
GRE reporter constructs (and other reporter constructs)
are well known to behave differently to endogenous pro-
moters. They contain multiple tandem GRE sequences,
and do not have the same complexity of regulation in
terms of chromatin structure and epigenetic regulation, or
the same regulation of expression by cofactors and sensi-
tivity to post-translational modifications of GRα, as do
endogenous GC inducible genes [31]. The complexity of
regulation of endogenous promoters may also explain the
differential effect of TGF-β on the panel of glucocorticoid-
inducible genes assessed; an observation consistent be-
tween both epithelial cell lines and primary differentiated
cells. The fact that TGF-β shows similar patterns of
regulation of glucocorticoid-inducible gene expression in
differentiated primary human bronchial epithelial cells
provides strong evidence of the potential for TGF-β to
regulate glucocorticoid action in situ in the airways of
glucocorticoid-resistant patients.
We examined tethering transrepressional mechanisms
through measuring GC regulation of inflammatory gene
expression and mediator release. In the presence and
absence of TGF-β, a similar degree of dexamethasone-
induced repression of IL-6 mRNA, IL-8 mRNA and
COX-2 mRNA in BEAS-2B cells, and COX-2 mRNA,
IL-6 mRNA, IL-6 protein, and PGE2 production in A549
cells was observed. It has been widely accepted that
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of pro-inflammatory genes, such as the genes encoding
COX2, IL-6 and IL-8, through a tethering transrepres-
sion of NFκB [33]. Therefore the lack of impairment by
TGF-β of the glucocorticoid regulation of these genes
could suggest that TGF-β has no effect on transrepres-
sional mechanisms. In contrast, we also found that TGF-β
decreased the percentage of inhibition by dexamethasone
of IL-1-induced IL-8 mRNA expression in A549 cells,
consistent with our previous study showing impaired IL-8
protein production in A549 cells [9] suggesting that under
some conditions glucocorticoid repressional mechanisms
may be impacted by TGF-β. However, the fact this impair-
ment was not observed in the BEAS-2B cell line suggests
that it may either be a cell-type-specific or stimulus-
specific phenomenon, or may be due to differing direct
effects of TGF-β on IL-8 expression, rather than a differ-
ence in the effect on glucocorticoid sensitivity.
Interestingly, it has been shown in A549 cells that dexa-
methasone does not inhibit IL-1-induced NFκB binding
for up to 2 h [34] and it has further been noted that gluco-
corticoid effects on mRNA stability and GRE-dependent
transactivation of induction of MKP-1, GILZ and IκBα,
the inhibitor of NFκB can manifest as repression of gene
transcription, without the involvement of transrepression
mechanisms [30,31]. It is plausible therefore that the im-
pairment of glucocorticoid regulation of IL-8 production
in A549 cells by TGF-β could be a further manifestation
of the impairment of transactivation process already
noted. Whilst this data cannot rule out an effect of TGF-β
on transrepression mechanisms, such an effect seems
highly improbable given the fact that TGF-β has no effect
on the glucocorticoid regulation of so many prototypical
transrepressionally controlled genes.
In the A549 cell line, TGF-β decreases both GRα ex-
pression and the nuclear translocation of GRα. There-
fore, the impairment of glucocorticoid activity may be,
but is not necessarily, partially attributable to a deficit of
GRα in the nucleus [9]. GRα protein expression is de-
creased by glucocorticoid treatment through the well-
described process of homologous down-regulation [35].
In this study, as expected, Dex treatment caused a de-
crease in GRα protein expression in the BEAS-2B cell
line. However, neither the basal expression of GRα, nor
its susceptibility to GC-induced down-regulation were
affected by TGF-β. Furthermore, the level of GRα
nuclear immunoreactivity and the rate and extent of
Dex-induced GRα-YFP nuclear translocation was un-
affected by TGF-β, suggesting that impaired nuclear
localization of GRα is not explanatory of TGF-β-induced
glucocorticoid insensitivity.
The phosphorylation state of GRα is known to impact
on transcriptional activity, receptor stability, association
with co-activators and co-repressors, and sub-cellularlocalization [22]. Altered GRα phosphorylation has been
associated with impaired glucocorticoid responsiveness in
airway smooth muscle cells [36]. Therefore, modulation of
GRα phosphorylation by TGF-β could account for the
effect of TGF-β in modulating glucocorticoid activity. We
found, however, that TGF-β (at a concentration that
results in complete suppression of GRE activity and sig-
nificant impairment of GC-inducible gene expression)
has no effect on the pattern of GRα phosphorylation at
Ser203, Ser211 or Ser226, the most well studied GRα
phosphorylation sites. Given the relevance of GRα
phosphorylation to nuclear localization, these further
observations are consistent with the finding that TGF-β
has no effect on GRα nuclear translocation in the BEAS-
2B cell line.
We have shown in this study that inhibiting the type 1
TGF-β receptor, ALK5 in the BEAS-2B cell line is able
to fully prevent the effect of TGF-β in impairing gluco-
corticoid transactivation, much like observations made
in the A549 cell line [9]. We therefore wanted to thor-
oughly examine the wide variety of downstream signal-
ling pathways activated by TGF-β, both canonical and
non-canonical, to unravel the underlying mechanism
through which this occurs. We targeted each of the vari-
ous kinases known to be activated by TGF-β, using well-
validated small molecule inhibitors at concentrations
that have been widely used by us and many other groups
over many years [9,15-19]. However, we were not able to
even partially mimic the effect of inhibiting the ALK5
receptor through inhibiting each individual known down-
stream pathway. The possibility of redundancy across the
signalling pathways would only be revealed by inhibiting
multiple pathways simultaneously. However, combining
various inhibitors together in logical and random combi-
nations similarly had no effect on TGF-β impairment of
GC action. In order to examine canonical TGF-β signal-
ling, we chose to knockdown the expression of Smad4, the
common signalling transducer of the canonical pathways.
Whilst we were able to knockdown Smad4 expression by
>70% and markedly impair both the activity of the Smad-
dependent promoter for SM22, and the expression of
PAI-1 mRNA, an endogenous Smad-regulated gene, nei-
ther GC-inducible gene expression, nor the impairment
of these genes by TGF-β was affected by Smad4 knock-
down. Since epigenetic regulation of gene expression
has been linked to mechanisms of glucocorticoid in-
sensitivity [37-39], we even investigated whether inhibitors
of DNA methylation or histone deacetylation would pre-
vent the GC impairment by TGF-β. However, these inhibi-
tors similarly had no effect on TGF-β impairment of
transactivation.
There are several potential explanations that remain.
Firstly, TGF-β may signal through Smad2/3-dependent
transcriptional activation in a Smad4-independent manner
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a role for Smad-dependent signalling. The ALK5 receptor
signalling pathway may also lead to downstream recruit-
ment of known GR co-activators such as glucocorticoid
receptor interacting protein 1 (GRIP-1), which has been
shown to prevent glucocorticoid transactivation in airway
smooth muscle cells [42], and is known to bind directly
to Smad3 [43]. Similarly, TGF-β induction of GR co-
repressors may mediate the transcriptional impairment
observed. It is also conceivable that in our attempt to
inhibit multiple signalling pathways simultaneously, we
either did not inhibit the correct combination of pathways,
or did not inhibit them in the correct temporal sequence
for their role to be identified. Finally, and in our view the
most plausible scenario is that there is a novel, non-
canonical pathway being activated that could not be iden-
tified through an hypothesis-driven approach. Functional
genomics or related operational approaches would there-
fore be required to determine the signalling cascade
through which TGF-β impairs glucocorticoid action.
In this study, we have demonstrated that TGF-β potently
induces insensitivity to glucocorticoid transactivation in
epithelial cells, without impacting on glucocorticoid trans-
repression. Demonstration of the interaction of glucocortic-
oid and TGF-β in air-liquid interface cultures of human
bronchial epithelium also raises the possibility of a mutual
physiologically significant antagonistic interaction of these
endogenous mediators during development, growth and
repair. We have demonstrated that glucocorticoid im-
pairment occurs downstream from the TGF-β receptor
(ALK5), but is not mediated by known canonical or
non-canonical pathways. Furthermore we provide data
showing this impairment is not a result of epigenetic
repression mechanisms, a theme that pervades recent
literature concerning mechanisms of glucocorticoid
resistance. This study therefore implicates novel TGF-
β-inducible mechanisms as targets to modulate gluco-
corticoid action, and thereby restore glucocorticoid
sensitivity. We consider it important to identify the
downstream signalling pathways responsible due to the
limitations of blocking TGF-β broadly. Since TGF-β ac-
tivates such a wide variety of signalling pathways, and is
involved in the homeostatic regulation of many cellular
processes, it is not surprising that many unwanted side-
effects develop from broadly blocking TGF-β action
[44]. Of particular concern is the development of wide-
spread inflammation and defects in autoimmunity
[45,46], as well as defective haematopoiesis and other
cardiovascular defects [47], demonstrated many years ago
in TGF-β1 knockout mice, and more recently using small
molecule ALK5 inhibitors in rats [48,49]. We believe that
since TGF-β-induced glucocorticoid insensitivity appears
to occur through a novel downstream signalling mechan-
ism, it could potentially be very selectively targeted torestore glucocorticoid activity, whilst avoiding the multi-
tude of potential side effects due to broadly inhibiting
TGF-β action. Identifying this mechanism therefore has
the potential to lead to new targets and novel treatments
for glucocorticoid resistant disease.
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